RBC Capital raised the firm’s price target on PTC Therapeutics (PTCT) to $63 from $60 and keeps an Outperform rating on the shares after its Q2 results. Translarna remains resilient and should help bridge the company into what the firm expects will be a strong Sephience launch, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $79 from $78 at Wells Fargo
- PTC Therapeutics Reports Q2 2025 Financial Results
- PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions
- PTC Therapeutics Enters Rights Satisfaction Agreement
- PTC Therapeutics Announces Q2 2025 Financial Results